Cure8 research brief
The work aims to improve colon-targeted delivery of an aminosalicylate (balsalazide) to boost local drug levels and protect the drug from gastric degradation—potentially relevant to people with ulcerative colitis looking for more effective local treatments.
Researchers developing IBD drug-delivery systems, formulation scientists, and clinicians interested in novel colon-targeted therapies for ulcerative colitis.
Researchers used a Box–Behnken experimental design to optimize hydrogel formulations made from beta-cyclodextrin, acrylic acid, and a cross-linker (MBA) and initiated polymerization with potassium persulfate.
Fifteen formulations were evaluated for swelling (highest at pH 7.2), drug entrapment (reported up to 96%), porosity, sol–gel fraction, and in vitro release up to about 8 hours.
Molecular docking between beta-cyclodextrin and balsalazide disodium was performed and described as showing good binding affinity, and characterization (FTIR, DSC, SEM) suggested stable, porous hydrogels without drug–excipient interaction. In vitro release data were modeled (Hixson–Crowell), consistent with geometry- and swelling-mediated release.
This is an in vitro formulation and characterization study (abstract-level reporting). It does not report animal or human clinical outcomes; docking and in vitro release are preliminary steps toward further preclinical testing.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors declare no conflicts of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
This trial tests whether a seaweed-derived fucoidan given with standard 5-ASA therapy can change biomarkers linked to mucosal healing (fecal calprotectin, fecal short-chain fatty acids) and stool consistency in people...
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...
